TY - JOUR AU - Fiorelli, Alfonso AU - Vitiello, Fabiana AU - Morgillo, Floriana AU - Santagata, Mario AU - Spuntarelli, Chiara AU - Domenico, Marina Di AU - Santini, Mario AU - Bianco, Andrea PY - 2019 TI - Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence? JF - Translational Cancer Research; Vol 8, Supplement 6 (December 20, 2019): Translational Cancer Research Y2 - 2019 KW - N2 - In the immunotherapy possibilities, pembrolizumab appeared as a leader, along with nivolumab and atezolizumab, in the second-line setting (1). In the last years, the results of phase III KEYNOTE trials (2-6) confirmed the Pembrolizumab as ahead of other checkpoint inhibitors in the first-line setting. Firstly, KEYNOTE-10 (7) showed that the PD-1 inhibitor represented a standard second-line treatment option in NSCLC as it significantly improved OS in comparison with docetaxel following prior platinum-based chemotherapy. UR - https://tcr.amegroups.org/article/view/29904